Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Curis Inc (CRIS) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 427,270
  • Shares Outstanding, K 129,470
  • Annual Sales, $ 7,880 K
  • Annual Income, $ -58,980 K
  • 36-Month Beta 1.88
  • Price/Sales 54.24
  • Price/Book 10.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +18.00%
on 11/07/16
3.72 -20.70%
on 11/15/16
+0.51 (+20.90%)
since 11/04/16
3-Month
1.70 +73.53%
on 09/06/16
3.72 -20.70%
on 11/15/16
+1.22 (+70.52%)
since 09/02/16
52-Week
1.25 +136.00%
on 02/11/16
3.72 -20.70%
on 11/15/16
+0.09 (+3.15%)
since 12/04/15

Most Recent Stories

More News
Curis Announces Full Approval of Roche's Erivedge(R) in the European Union

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that the European...

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced the appointment...

Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today presented preliminary...

Biotech Stocks Under Scanner -- bluebird bio, Corbus Pharma, Curis, and Cascadian Therapeutics

On Wednesday, November 2, 2016, the NASDAQ Composite ended the trading session at 5,105.57, down 0.93%; the Dow Jones Industrial Average edged 0.43% lower, to finish at 17,959.64; and the S&P 500 closed...

Curis Reports Third Quarter 2016 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial...

Humana (HUM) Likely to Top Q3 Earnings; Stock to Gain?

We expect Humana Inc. (HUM) to beat expectations when it reports third-quarter results on Nov 4, before the market opens.

Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will...

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that...

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2 oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration

Curis (CRIS) Shows Strength: Stock Adds 6.9% in Session

Curis, Inc. (CRIS) moved big last session, as its shares jumped almost 7% on the day.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Support & Resistance

2nd Resistance Point 3.10
1st Resistance Point 3.03
Last Price 2.95
1st Support Level 2.88
2nd Support Level 2.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.